• 1
    Rickinson AB,Kieff E. Epstein-Barr virus. In: FieldsBN, ed. Fields virology,4th edn. New York (NY): Lippincott Williams and Wilkins, 2001. Vol. 1, 2575627.
  • 2
    Kieff E,Rickinson AB. Epstein-Barr virus and replication. In: FieldsBN, ed. Fields virology,4th ed. New York (NY): Lippincott Williams and Wilkins, 2001. Vol. 1, 251173.
  • 3
    Zur Hausen H,Schulte-Holthausen H. Presence of EB virus nucleic acid homology in a “virus-free” line of Burkitt tumour cells. Nature 1970; 227: 24548.
  • 4
    Nonoyama M,Pagano JS. Homology between Epstein-Barr virus DNA and viral DNA from Burkitt's lymphoma and nasopharyngeal carcinoma determined by DNA-DNA reassociation kinetics. Nature 1973; 242: 447.
  • 5
    Rowe M,Lear AL,Croom-Carter D,Davies AH,Rickinson AB. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. J Virol 1992; 66: 12231.
  • 6
    Yamamoto N,Takizawa T,Iwanaga Y,Shimizu N,Yamamoto N. Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs. FEBS Lett 2000; 484: 15358.
  • 7
    Mosialos G,Birkenbach M,Yalamanchili R,VanArsdale T,Ware C,Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995; 80: 38999.
  • 8
    Mori N,Fujii M,Ikeda S,Yamada Y,Tomonaga M,Ballard DW,Yamamoto N. Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood 1999; 93: 23608.
  • 9
    Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1999; 14: 64981.
  • 10
    Guinness ME,Kenney JL,Reiss M,Lacy J. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice. Cancer Res 2000; 60: 53548.
  • 11
    Miyake A,Dewan MZ,Ishida T,Watanabe M,Honda M,Sata T,Yamamoto N,Umezawa K,Watanabe T,Horie R. Induction of apoptosis in Epstein-Barr virus-infected B-lymphocytes by the NF-kappaB inhibitor DHMEQ. Microbes Infect 2008; 10: 74856.
  • 12
    Watanabe M,Dewan MZ,Okamura T,Sasaki M,Itoh K,Higashihara M,Mizoguchi H,Honda M,Sata T,Watanabe T,Yamamoto N,Umezawa K, et al. A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int J Cancer 2005; 114: 328.
  • 13
    Adams J,Palombella VJ,Elliott PJ. Proteasome inhibition: a new strategy in cancer treatment. Invest New Drugs 2001; 18: 10921.
  • 14
    Teicher BA,Ara G,Herbst R,Palombella VJ,Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 263845.
  • 15
    Hideshima T,Chauhan D,Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002; 277: 1663947.
  • 16
    Dewan MZ,Terashima K,Taruishi M,Hasegawa H,Ito M,Tanaka Y,Mori N,Sata T,Koyanagi Y,Maeda M,Kubuki Y,Okayama A, et al. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/γcnull mice: suppression by an inhibitor against NF-κB. J Virol 2003; 77: 528694.
  • 17
    Kitajima I,Shinohara T,Bilakovics J,Brown DA,Xu X,Nerenberg M. Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-κB. Science 1992; 258: 17925.
  • 18
    Mori N,Yamada Y,Ikeda S,Yamasaki Y,Tsukasaki K,Tanaka Y,Tomonaga M,Yamamoto N,Fujii M. Bay 11–7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells. Blood 2002; 100: 182834.
  • 19
    Tan C,Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002; 62: 10836.
  • 20
    Dewan MZ,Uchihara JN,Terashima K,Honda M,Sata T,Ito M,Fujii N,Uozumi K,Tsukasaki K,Tomonaga M,Kubuki Y,Okayama A, et al. Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir. Blood 2006; 107: 71624.
  • 21
    Cahir-McFarland ED,Davidso DM,Schauer SL,Duong J,Kieff E. NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 2000; 97: 605560.
  • 22
    Collier AC. Efficacy of combination antiretroviral therapy. Adv Exp Med Biol 1996; 394: 35572.
  • 23
    Collier AC,Coombs RW,Schoenfeld DA,Bassett R,Baruch A,Corey L. Combination therapy with zidovudine, didanosine and saquinavir. Antiviral Res 1996; 29: 99.
  • 24
    Collier AC,Coombs RW,Schoenfeld DA,Bassett RL,Timpone J,Baruch A,Jones M,Facey K,Whitacre C,McAuliffe VJ,Friedman HM,Merigan TC, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996; 334: 101117.
  • 25
    Markowitz M,Saag M,Powderly WG,Hurley AM,Hsu A,Valdes JM,Henry D,Sattler F,La Marca A,Leonard JM,Ho DD. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333: 153439.
  • 26
    Kempf DJ,Marsh KC,Denissen JF,McDonald E,Vasavanonda S,Flentge CA,Green BE,Fino L,Park CH,Kong XP,Wideburg NE,Saldivar A, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995; 92: 248488.
  • 27
    Andre P,Groettrup M,Klenerman P,de Giuli R,Booth BL,Jr,Cerundolo V,Bonneville M,Jotereau F,Zinkernagel RM,Lotteau V. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci USA 1998; 95: 1312024.
  • 28
    Liang JS,Distler O,Cooper DA,Jamil H,Deckelbaum RJ,Ginsberg HN,Sturley SL. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 2001; 7: 132731.
  • 29
    Schmidtke G,Holzhütter HG,Bogyo M,Kairies N,Groll M,de Giuli R,Emch S,Groettrup M. How an inhibitor of the HIV-I protease modulates proteasome activity. J Biol Chem 1999; 274: 3573440.
  • 30
    Gaedicke S,Firat-Geier E,Constantiniu O,Lucchiari-Hartz M,Freudenberg M,Galanos C,Niedermann G. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis. Cancer Res 2002; 62: 69018.
  • 31
    Pati S,Pelser CB,Dufraine J,Bryant JL,Reitz JMS,Weichold FF. Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 2002; 99: 37719.
  • 32
    Sgadari C,Barillari G,Toschi E,Carlei D,Bacigalupo I,Baccarini S,Palladino C,Leone P,Bugarini R,Malavasi L,Cafaro A,Falchi M, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 8: 22532.
  • 33
    Katano H,Pesnicak H,Cohen JI. Simvastatin induces apoptosis of Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines and delays development of EBV lymphomas. Proc Natl Acad Sci USA 2004; 101: 49605.
  • 34
    Norvir, Ritonavir Product monograph. North Chicago, IL: Abbott laboratories, 1997.
  • 35
    Gatti G,Di Biagio A,Casazza R,De Pascalis C,Bassetti M,Cruciani M,Vella S,Bassetti D. The relationship between ritonavir plasma levels and side-effects: implications for therapeutic drug monitoring. AIDS 1999; 13: 20839.